Blumental S.,Free University of Colombia |
Sabbe M.,Scientific Institute of Public Health SIPH |
Lepage P.,Free University of Colombia |
Asscherickx W.,Algemeen Ziekenhuis Diest |
And 100 more authors.
Archives of Disease in Childhood | Year: 2016
Background: Varicella universal vaccination (UV) has been implemented in many countries for several years. Nevertheless, varicella UV remains debated in Europe and few data are available on the real burden of infection. We assessed the burden of varicella in Belgium through analysis of hospitalised cases during a 1-year period. Methods: Data on children admitted to hospital with varicella were collected through a national network from November 2011 to October 2012. Inclusion criteria were either acute varicella or related complications up to 3 weeks after the rash. Results: Participation of 101 hospitals was obtained, covering 97.7% of the total paediatric beds in Belgium. 552 children were included with a median age of 2.1 years. Incidence of paediatric varicella hospitalisations reached 29.5/105 person-years, with the highest impact among those 0-4 years old (global incidence and odds of hospitalisation: 79/105 person-years and 1.6/100 varicella cases, respectively). Only 14% (79/552) of the cohort had an underlying chronic condition. 65% (357/552) of children had ≥ 1 complication justifying their admission, 49% were bacterial superinfections and 10% neurological disorders. Only a quarter of children (141/552) received acyclovir. Incidence of complicated hospitalised cases was 19/105 person-years. Paediatric intensive care unit admission and surgery were required in 4% and 3% of hospitalised cases, respectively. Mortality among Belgian paediatric population was 0.5/106 and fatality ratio 0.2% among our cohort. Conclusions: Varicella demonstrated a substantial burden of disease in Belgian children, especially among the youngest. Our thorough nationwide study, run in a country without varicella UV, offers data to support varicella UV in Belgium.
Lum L.C.S.,University of Malaya |
Borja-Tabora C.F.,Manila Doctors Hospital |
Breiman R.F.,International Center for Diarrhoeal Disease Research |
Vesikari T.,University of Tampere |
And 22 more authors.
Vaccine | Year: 2010
Children aged 11 to <24 months received 2 intranasal doses of live attenuated influenza vaccine (LAIV) or placebo, 35 ± 7 days apart. Dose 1 was administered concomitantly with a combined measles, mumps, and rubella vaccine (Priorix). Seroresponses to measles and mumps were similar between groups. Compared with placebo, response rates to rubella in LAIV + Priorix recipients were statistically lower at a 15 IU/mL threshold (83.9% vs 78.0%) and the prespecified noninferiority criteria were not met. In a post hoc analysis using an alternate widely accepted threshold of 10 IU/mL, the noninferiority criteria were met (93.4% vs 89.8%). Concomitant administration with Priorix did not affect the overall influenza protection rate of LAIV (78.4% and 63.8% against antigenically similar influenza strains and any strain, respectively). © 2009 Elsevier Ltd. All rights reserved.
Van Loo S.,Sint Vincentiusziekenhuis |
Vanderputte S.,Sint Vincentiusziekenhuis
Acta Chirurgica Belgica | Year: 2013
Due to the increase in screening programs, more rectal polyps and early rectal cancers are detected. Transanal resection of these lesions is less invasive than a transabdominal approach. Transanal endoscopic microsurgery (TEM) has gained a lot of interest, but the technique has several drawbacks such as the expensive instrumentation and considerable learning curve. With the evolution of single incision laparoscopic surgery (SILS), laparo-endoscopic single-site surgery (LESS) and natural orifice transluminal endoscopic surgery (NOTES), new devices have become available. This led to the development of a hybrid technique of transanal surgery. The technique combines a transanal approach, a SILS port and standard laparoscopic instruments. We used this technique in 2 cases. © Acta Chirurgica Belgica 2013.
Van Loo S.,Sint Vincentiusziekenhuis |
Boeykens E.,Sint Vincentiusziekenhuis |
Stappaerts I.,Sint Vincentiusziekenhuis |
Rutsaert R.,Sint Vincentiusziekenhuis
Lung Cancer | Year: 2011
Pulmonary blastomas are rare malignant tumors, comprising only 0.25-0.5% of all malignant lung neoplasms. Pulmonary blastomas are subdivided in three categories: well-differentiated fetal adenocarcinoma (WDFA), classic biphasic pulmonary blastoma (CBPB) and pleuropulmonary blastoma (PPB), which is currently regarded as a separate entity. The majority of patients with CBPB and WDFA are adults with an average age of 43 years. Tobacco use is identified as a causative agent. Symptomatology varies from asymptomatic (40%) to symptoms of a non-specific pulmonary disease. The most common roentgenologic pattern is a large peripheral nodule. The treatment of choice is surgical excision. The efficacy of adjuvant chemotherapy and radiotherapy is not yet established. The prognosis of pulmonary blastoma is very poor; overall five-year survival is 16%. WDFA appears to have a better prognosis. Adverse prognostic factors are biphasic type, tumor recurrence, metastasis at initial presentation, gross size of the tumor (>5. cm) and lymph node metastasis. On the basis of the available literature, an initial aggressive treatment that includes surgery and, wherever possible, postoperative chemotherapy and radiotherapy could be useful to prolong survival in patients with this rare lung neoplasm. We present a case of classic biphasic pulmonary blastoma in a 77-year old male and review the literature. © 2011 Elsevier Ireland Ltd.